Belgian radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.
Redectane is a radiolabeled antibody detected by PET for the diagnosis of renal cell cancer. It currently is in phase III clinical trials.
IBA also will be responsible for manufacturing Redectane and will pay Wilex an initial fee, milestone payments, and other considerations as part of the agreement.
Copyright © 2008 AuntMinnie.com